News & Events

Finances

Xeltis receives commitment from Grand Pharma to invest €15M

The Chinese company Grand Pharmaceutical Group Ltd (0512.HK) has committed to invest €15 million in equity and license fees, as…

Content TeamAugust 9, 2022

Publications

Pivotal Study protocol publication for aXess hemodialysis graft

The protocol for our ongoing Pivotal Study for the aXess hemodialysis graft has been published in the Journal of Vascular…

Content TeamMay 30, 2022

Publications

Novel in vivo imaging of Xeltis devices advances understanding of ETR – in Frontiers

Results from novel imaging analysis of the Endogenous Tissue Restoration (ETR) process in Xeltis’ devices further advance the understanding of…

Content TeamMay 3, 2022

Featured

aXess and new directions for vascular access grafts

Renal Interventions dedicated a feature article to arteriovenous grafts (AVG) for hemodialysis access, in which Xeltis’ restorative AVG graft aXess…

Content TeamApril 8, 2022

Publications

Xeltis pioneers supramolecular materials for cardiovascular restoration in patients

Xeltis’ devices are the first living applications of supramolecular materials for cardiovascular restoration in patients. An article published in peer-reviewed…

Content TeamApril 5, 2022

Clinical Trials

XABG preclinical trial showed superior performance vs harvested veins at one year

Results from preclinical trials of Xeltis restorative coronary artery bypass graft XABG showed superior performance of the Xeltis graft compared…

Content TeamMarch 11, 2022

Featured

Vascular experts discuss aXess in dialysis patients

Matteo Tozzi, MD, vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD,…

Content TeamJanuary 12, 2022

Finances

Xeltis receives €15M funding from EIC Accelerator

Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission.…

Content TeamDecember 21, 2021

Finances

Xeltis lands €15 million European financing from EIB

The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will…

Content TeamNovember 22, 2021

Publications

ETR Insights from Xeltis restorative pulmonary valve in Acta Biomaterialia

The latest insights on the fascinating mechanisms behind endogenous tissue restoration (ETR), the process that transforms Xeltis devices into living…

Content TeamOctober 14, 2021

Publications

Superior biocompatibility of Xeltis materials vs conventional heart valve devices published in JBMR

Xeltis’ polymers have shown superior pro-healing response and no calcification compared to conventional biological heart valve devices in preclinical trial…

Content TeamAugust 6, 2021

Publications

Excellent performance and safety data on Xeltis bio-restorative technology published

Promising early outcomes from two clinical trials of Xeltis pulmonary valve confirm the excellent safety and performance of its bio-restorative…

Content TeamMarch 12, 2021

Events

Xeltis living heart valves to epitomize innovative medtech at the Spirit of Bern

Xeltis has been selected with three other Swiss companies to illustrate how medtech innovation can pave new ways to improve…

Content TeamFebruary 25, 2021

Finances

Xeltis’ closes €10.5 million Series D financing

Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The…

Content TeamSeptember 5, 2019

Publications

Xeltis’ RestoreX™ in Cardiovascular Pathology

Peer-reviewed journal Cardiovascular Pathology published positive one-year in-vivo data on Xeltis’ RestoreX™ technology platform in its latest issue. According to…

Content TeamMarch 8, 2019

Clinical Trials

Xeltis starts the pivotal clinical trial for aXess

Xeltis has started the pivotal trial for the first-ever restorative synthetic hemodialysis access grafts, aXess. The first two patients have…

Content TeamNovember 10, 2022

Clinical Trials

XABG unprecedented preclinical outcomes for a CABG device may outperform saphenous veins

Preclinical data on Xeltis restorative Coronary Artery Bypass Graft (CABG) device, XABG, show unprecedented one-year patency for a CABG device,…

Content TeamNovember 9, 2022

Clinical Trials

XABG preclinical trial showed superior performance vs harvested veins at one year

Results from preclinical trials of Xeltis restorative coronary artery bypass graft XABG showed superior performance of the Xeltis graft compared…

Content TeamMarch 11, 2022

Keep up to date with all of our latest news and events

LATEST NEWS

Xeltis raises an additional €20.5m of funding to advance aXess^™ toward FDA approval and US commercial launch

Xeltis receives commitment from Grand Pharma to invest €15M

Pivotal Study protocol publication for aXess hemodialysis graft

Novel in vivo imaging of Xeltis devices advances understanding of ETR – in Frontiers

aXess and new directions for vascular access grafts

Xeltis pioneers supramolecular materials for cardiovascular restoration in patients

XABG preclinical trial showed superior performance vs harvested veins at one year

Vascular experts discuss aXess in dialysis patients

Xeltis receives €15M funding from EIC Accelerator

Xeltis lands €15 million European financing from EIB

ETR Insights from Xeltis restorative pulmonary valve in Acta Biomaterialia

Superior biocompatibility of Xeltis materials vs conventional heart valve devices published in JBMR

Excellent performance and safety data on Xeltis bio-restorative technology published

Xeltis living heart valves to epitomize innovative medtech at the Spirit of Bern

Xeltis’ closes €10.5 million Series D financing

Xeltis’ RestoreX™ in Cardiovascular Pathology

Xeltis starts the pivotal clinical trial for aXess

XABG unprecedented preclinical outcomes for a CABG device may outperform saphenous veins

XABG preclinical trial showed superior performance vs harvested veins at one year

Press Releases

Xeltis starts pivotal clinical trial with first ever restorative synthetic hemodialysis access graft

Xeltis presents promising FIH data on restorative hemodialysis access graft at ESVS congress

Xeltis receives commitment from Grand Pharma to invest €15M

Xeltis lands €15 million European financing from EIB

Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

Media

Restorex^® Platform Film

Pulmonary Heart Valve

aXess^™ EU Pivotal Trial

Professor Thierry Carrel

Martijn Cox

Professor Jean-Marie Lehn

A Patient’s Perspective

Global Impact of Heart Valve Disease

NEWS & EVENTS

Keep up to date with all of our latest news and events

LATEST NEWS

Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch

Press Releases

Xeltis starts pivotal clinical trial with first ever restorative synthetic hemodialysis access graft

Xeltis presents promising FIH data on restorative hemodialysis access graft at ESVS congress

Xeltis receives commitment from Grand Pharma to invest €15M

Xeltis lands €15 million European financing from EIB

Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

Media

Restorex® Platform Film

Pulmonary Heart Valve

aXess™ EU Pivotal Trial

Professor Thierry Carrel

Martijn Cox

Professor Jean-Marie Lehn

A Patient’s Perspective

Global Impact of Heart Valve Disease

Xeltis raises an additional €20.5m of funding to advance aXess^™ toward FDA approval and US commercial launch

Restorex^® Platform Film

aXess^™ EU Pivotal Trial